OP0595, a new diazabicyclooctane: mode of action as a serine β-lactamase inhibitor, antibiotic and β-lactam 'enhancer'
about
New β-Lactamase Inhibitors in the ClinicEndless Resistance. Endless Antibiotics?Antibiotics in the clinical pipeline at the end of 2015.Distinctive Binding of Avibactam to Penicillin-Binding Proteins of Gram-Negative and Gram-Positive Bacteria.The road to avibactam: the first clinically useful non-β-lactam working somewhat like a β-lactam.What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.In Vitro and In Vivo Activities of OP0595, a New Diazabicyclooctane, against CTX-M-15-Positive Escherichia coli and KPC-Positive Klebsiella pneumoniae.ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii.Bifunctional antimicrobial conjugates and hybrid antimicrobials.Efficacy and Pharmacokinetics of the Combination of OP0595 and Cefepime in a Mouse Model of Pneumonia Caused by Extended-Spectrum-Beta-Lactamase-Producing Klebsiella pneumoniae.WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases.WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones.In vitro and in vivo activities of the diazabicyclooctane OP0595 against AmpC-derepressed Pseudomonas aeruginosa.Interactions of OP0595, a Novel Triple-Action Diazabicyclooctane, with β-Lactams against OP0595-Resistant Enterobacteriaceae Mutants.Activity of OP0595/β-lactam combinations against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing β-lactamases.AmpC β-lactamase induction by avibactam and relebactam.The frequency and mechanism of spontaneous resistance to sulbactam combined with the novel β-lactamase inhibitor ETX2514 in clinical isolates of Acinetobacter baumannii.Investigational drugs in phase I and phase II clinical trials for the treatment of community-acquired pneumonia.Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates.New insights into the regulatory pathways associated with the activation of the stringent response in bacterial resistance to the PBP2-targeted antibiotics, mecillinam and OP0595/RG6080.Structural Insights into the TLA-3 Extended-Spectrum β-Lactamase and Its Inhibition by Avibactam and OP0595.Exploring Additional Dimensions of Complexity in Inhibitor Design for Serine β-Lactamases: Mechanistic and Intra- and Inter-molecular Chemistry Approaches.β-lactam/β-lactamase inhibitor combinations: an updateFirst Penicillin-Binding Protein Occupancy Patterns of β-Lactams and β-Lactamase Inhibitors in Klebsiella pneumoniae
P2860
Q26747150-EBAD421D-1B57-411B-87C4-3D5D5808B0C0Q28822179-4C0834D7-9FFC-4A02-A6D5-BD0FA7613530Q30249262-65BC335D-6349-45C1-8DAB-FED2BC7B2E7BQ38367722-6FAD0BFC-E5B5-41E7-9817-954724EBA2DDQ38850240-8B8A2E2C-4C90-4AEE-8754-AD9B3D66AF52Q39120027-045C7E6E-3AB5-46A5-AF36-3792D09D0843Q39940279-882672B7-59A2-4B97-84BC-CD49A5EF35D7Q40152356-0EA3312C-EBB8-48A4-A4E6-090CEB283C41Q40203926-9740AC18-92B5-4686-96FE-2CEBB1A8BF85Q40211709-871CF8E7-7D1C-4533-8797-DA4BC46BCD6EQ40282005-5DE7A89D-8BDA-47AB-889B-FA667D73DC82Q40296000-AC18CDAA-388B-4AED-A949-271AEBD9FD61Q40401367-7653D2F1-3E1C-43D5-B64E-296FC142C90DQ40916464-EE238ED8-754B-46D6-8FBD-D756E9E7928AQ41031284-090A0651-6988-4DC9-8597-F9165692E27CQ41992904-878BF151-CA35-42D5-8196-518A1964983BQ47406932-C2825EA6-F52D-45D4-8C0C-4AAD06074FD2Q47761002-F0CF5E95-7DC9-4174-9A40-A1FFAAC1DBA9Q47785464-661E2547-5EA5-4235-A36B-80F9DDF0EEA7Q48517073-6FFCAE08-BBD9-4071-99D8-36371750E9BAQ48713306-5A18C442-C353-44D9-8CE0-CD1DFF58A37AQ52314903-8C545736-F2C1-4319-AFF2-C19CF0DA1F63Q57133147-9633649A-21BA-48D4-A0D1-DBC95FC2250CQ57240386-C107C74C-5212-410B-9B71-42F6CB723DE6
P2860
OP0595, a new diazabicyclooctane: mode of action as a serine β-lactamase inhibitor, antibiotic and β-lactam 'enhancer'
description
2015 nî lūn-bûn
@nan
2015 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
OP0595, a new diazabicycloocta ...... biotic and β-lactam 'enhancer'
@ast
OP0595, a new diazabicycloocta ...... biotic and β-lactam 'enhancer'
@en
OP0595, a new diazabicycloocta ...... biotic and β-lactam 'enhancer'
@nl
type
label
OP0595, a new diazabicycloocta ...... biotic and β-lactam 'enhancer'
@ast
OP0595, a new diazabicycloocta ...... biotic and β-lactam 'enhancer'
@en
OP0595, a new diazabicycloocta ...... biotic and β-lactam 'enhancer'
@nl
prefLabel
OP0595, a new diazabicycloocta ...... biotic and β-lactam 'enhancer'
@ast
OP0595, a new diazabicycloocta ...... biotic and β-lactam 'enhancer'
@en
OP0595, a new diazabicycloocta ...... biotic and β-lactam 'enhancer'
@nl
P2093
P2860
P356
P1476
OP0595, a new diazabicycloocta ...... biotic and β-lactam 'enhancer'
@en
P2093
Akihiro Morinaka
David M Livermore
Kenji Suzuki
Mototsugu Yamada
Nakako Mitsuhashi
Seiichi Inamura
Takashi Ida
Takashi Watanabe
Takeshi Furuuchi
P2860
P304
P356
10.1093/JAC/DKV166
P407
P577
2015-10-01T00:00:00Z